Since restoration of dystrophin is the major goal of all current therapies tested for DMD, in this report we have confirmed increased dystrophin expression in the heart, diaphragm and gastrocnemius muscle at 180 days after systemic administration of DEC to the mdx/scid mice. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.